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Abstract 
Background: Discovery of potent inhibitors of urease (jack bean) enzyme is the first step in the development of 
drugs against diseases caused by ureolytic enzyme.
Results: Thirty‑two derivatives of barbituric acid as zwitterionic adducts of diethyl ammonium salts were synthe‑
sized. All synthesized compounds (4a–z and 5a–s) were screened for their in vitro inhibition potential against urease 
enzyme (jack bean urease). The compounds 4i (IC50 = 17.6 ± 0.23 µM) and 5l (IC50 = 17.2 ± 0.44 µM) were found to 
be the most active members of the series, and showed several fold more urease inhibition activity than the stand‑
ard compound thiourea (IC50 = 21.2 ± 1.3 µM). Whereas, compounds 4a–b, 4d–e, 4g–h, 4j–4r, 4x, 4z, 5b, 5e, 5k, 
5n–5q having IC50 values in the range of 22.7 ± 0.20 µM–43.8 ± 0.33 µM, were also found as potent urease inhibitors. 
Furthermore, Molecular Dynamics simulation and molecular docking studies were carried out to analyze the binding 
mode of barbituric acid derivatives using MOE. During MD simulation enol form is found to be more stable over its 
keto form due to their coordination with catalytic Nickel ion of Urease. Additionally, structural–activity relationship 
using automated docking method was applied where the compounds with high biological activity are deeply buried 
within the binding pocket of urease. As multiple hydrophilic crucial interactions with Ala169, KCX219, Asp362 and 
Ala366 stabilize the compound within the binding site, thus contributing greater activity.
Conclusions: This research study is useful for the discovery of economically, efficient viable new drug against infec‑
tious diseases.
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Background
Urease is a nickel containing enzyme produced by plants, 
fungi, algae, and bacteria. It is involved in nitrogen turno-
ver and in crop fertilization, as well as in human and ani-
mal pathologies. Urease catalyse the hydrolysis of urea 
in its ammonia and carbon dioxide. Beside its medical, 
ecological and economical significances as urease has 
historical significances as it was the first enzyme to be 
crystallised in 1926 by Sumner [1–3]. Since its discovery 
in plants [4], Canavalia ensiformis (Fabaceae) urease has 
been exhaustively investigated [5]. Its activity is strictly 
dependent on nickel ions (Ni2+) [6]. The first X-ray dif-
fraction based structure of a urease was reported by Jabri 
and coworkers in 1995 from Klebsiella aerogenes [7]. 
Later on, other structures for ureases from Bacillus pas-
teurii [8], Helicobacter pylori [9] and C. ensiformis [10] 
were reported. The elucidation of the urease structure 
from a legume (jack bean) was crucial to better under-
stand the requirements for ureolytic activity of this class 
of enzymes in different organisms [10] were reported.
Urease enzyme is a virulence factor in certain human 
and animal ailments. It contributes to the development 
of kidney stones, pyelonephritis, peptic ulcers leading 
to gastric cancers, and other diseases [11]. It also causes 
the pathogenesis of hepatic coma urolithiasis, hepatic 
encephalopathy, pyelonephritis, ammonia and urinary 
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catheter encrustation [12, 13]. The gastric cancer [14, 15] 
is the fourth most common cancer and the second most 
common cause of cancer-related deaths worldwide [16]. 
It is often resulted from pathologies due to Helicobacter 
pylori. Urease lets bacteria to persist at the low pH of the 
stomach during colonization and lead to pathogenesis of 
gastric and peptic ulcers which in the long run may cause 
cancer [17]. The treatment of infection caused by ureo-
lytic bacteria with antimicrobials, however, often proved 
to be unsuccessful [13]. The barbiturates possessed a 
wide range of pharmacological applications, such as anti-
convulsant, sedative, anxiolytic, urease inhibition [18], 
antifungal [19], antimicrobial [20, 21], antitumor, antivi-
ral [13, 22] anti tuberculosis [23], mushroom tyrosinase 
inhibition [24], radio-sensitization [25], anti-inflamma-
tory, anticancer [26], anesthetic [27], diaminopimelate 
aminotransferase inhibition [28], and anti-proliferative 
activities [29].
Based on the therapeutic and pharmacological sig-
nificances of urease inhibition, our research group 
is involved in the search of simple but biologically 
interesting molecules that are easy to synthesize in 
just fewer steps with high yields. This type of chem-
istry is easily adopted by the pharmaceutical industry 
for commercialization. Previously, our research group 
reported zwitterionic adduct derived from barbituric 
acid as NO scavenger [30]. In view of these studies; the 
combined use of green synthetic technology for the 
high yield production of novel pharmacophoric barbi-
turic acid derivatives and their systematic evalution of 




All chemicals were purchased from Sigma-Aldrich, Fluka 
etc., and were used without further purification, unless 
otherwise stated. All melting points were measured on a 
Gallenkamp melting point apparatus in open glass capil-
laries and are uncorrected. IR Spectra were measured as 
KBr pellets on a Nicolet 6700 FT-IR spectrophotometer. 
The NMR spectra were recorded on a Varian Mercury 
Jeol-400 NMR spectrometer. 1H-NMR (400  MHz), and 
13C-NMR (100 MHz) were run in deuterated chloroform 
(CDCl3). Chemical shifts (δ) are referred in terms of ppm 
and J-coupling constants are given in Hz. Mass spectra 
were recorded on a Jeol JMS-600 H. Elemental analysis 
was carried out on Elmer 2400 Elemental Analyzer in 
CHN mode
Synthesis of 4 and 5 (GP1)
A mixture of 1 (3 mmol) and aldehyde 2 (1.5 mmol), as 
well as Et2NH (1.5  mmol, 155 μL) were placed in 3  mL 
of degassed H2O. The reaction mixture was kept at rt 
up to 5  h under stirring. After completion of the reac-
tion, monitored by TLC, the solid product was filtered, 
washed with ether (3 × 20 mL) and dried to obtain pure 




4a, as colorless crystal (1.5  g, 2.76  mmol, 92  %). IR 
(cm−1): 3450, 3000, 2872, 1670, 1582, 1510, 1466, 1384, 
1339; 1H-NMR (CDCl3, 400  MHz) 17.58 (s, 1H, OH), 
9.90(s, 1H, CHO), 7.73 (d, 2H, J =  8.0  Hz, Ph), 7.29 (d, 
2H, J = 8.0 Hz, Ph), 5.93(s, 1H, benzyl-H), 3.33 (s, 12H, 
4CH3), 3.06 (q, 4H, J  =  7.3  Hz, CH2CH3), 1.27 (t, 6H, 
J  =  7.3  Hz, CH2CH3); 13C-NMR (100  MHz, CDCl3): 
δ = 192.2, 165.3, 164.4, 151.7, 150.3, 134.3, 129.9, 127.3, 
91.7, 42.2, 35.1, 29.0, 28.7, 11.5; Anal. for C24H31N5O7; 
Calcd: C, 57.48; H, 6.23; N, 13.96; Found:C, 57.50; H, 




4b; rose-colored crystalline materials. m.p.: 135  °C; 
(97  %, 1.41  g, 2.91  mmol). IR (KBr, cm−1): 3455, 3201, 
2988, 1693, 1667, 1611, 1573, 1443; 1H-NMR (400 MHz, 
CDCl3): δ17.62 (s, 1H, OH), 7.10 (t, 1H, J = 7.3 Hz, Ph), 
6.92 (d, 1H, J = 7.3 Hz, Ph), 6.88 (d, 1H, J = 7.3 Hz, Ph), 
5.82(s, 1H, benzyl-H), 3.32 (s, 12H, 4CH3), 3.01 (q, 4H, 
J  =  7.3  Hz, CH2CH3), 2.25 (s, 3H, CH3), 1.26 (t, 6H, 
J  =  7.3  Hz, CH2CH3); 13C-NMR (100  MHz, CDCl3): 
δ = 165.3, 164.4, 151.8, 141.7, 137.4, 127.9, 127.1, 126.4, 
123.6, 92.1, 42.0, 34.4, 28.9, 28.6, 21.8, 11.4; Anal. for 
C24H35N5O6; Calcd: C, 59.12; H, 6.82; N, 14.36; Found: C, 




4c; a yellow powder; m.p.: 195  °C; (87  %, 1.35  g, 
2.61 mmol); IR (KBr, cm−1): 3453, 3205, 2987, 2904, 1675, 
1608, 1576, 1511, 1438, 1343, 1254;1H-NMR (400 MHz, 
CDCl3): δ17.58 (s, 1H, OH), 8.08 (d, 2H, J = 8.8 Hz, Ph), 
7.29 (d, 2H, J = 8.8 Hz, Ph), 5.95(s, 1H, benzyl-H), 3.34 
(s, 12H, 4CH3), 3.07 (q, 4H, J = 7.3 Hz, CH2CH3), 1.29 (t, 
6H, J = 7.3 Hz, CH2CH3); 13C-NMR (100 MHz, CDCl3): 
δ =  165.2, 164.4, 151.6, 150.8, 146.1, 127.5, 123.5, 91.4, 
42.2, 34.9, 28.9, 28.7, 11.5; Anal. for C23H30N6O8; Calcd: 
C, 53.28; H, 5.83; N, 16.21; Found: C, 53.29; H, 5.85; N, 
16.23; LC/MS (ESI): m/z = 518[M]+.
A suitable crystal for X-ray diffraction analysis was 
obtained from DCM/Et2O after 24  h. CCDC-1001798 
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4d; rose-colored crystalline materials; m.p.: 160  °C; 
(90  %, 1.35  g, 2.7  mmol). IR (KBr, cm−1): 3445, 3195, 
2977, 2836, 1689, 1664, 1613, 1504, 1447, 1378, 1242; 
1H-NMR (400  MHz, CDCl3): δ17.67 (s, 1H, OH), 7.01 
(d, 2H, J  =  8.8  Hz, Ph), 6.75 (d, 2H, J  =  8.8  Hz, Ph), 
5.79(s, 1H, benzyl-H), 3.33 (s, 12H, 4CH3), 2.99 (q, 4H, 
J = 7.3 Hz, CH2CH3), 1.26 (t, 6H, J = 7.3 Hz, CH2CH3); 
13C-NMR (100  MHz, CDCl3): δ  =  165.3, 164.3, 157.4, 
151.7, 133.6, 132.0, 127.4, 114.3, 92.1, 55.6, 42.1, 33.8, 
28.9, 11.5; Anal. for C24H33N5O7; Calcd: C, 57.25; H, 





4e; colorless crystalline materials; m.p.: 169  °C; (92  %, 
1.5  g, 2.76  mmol). IR (KBr, cm−1): 3450, 3120, 2982, 
1694, 1667, 1615, 1577, 1445, 1250; 1H-NMR (400 MHz, 
CDCl3): δ17.63 (s, 1H, OH), 7.22 (d, 1H, J = 7.3 Hz, Ph), 
7.19 (s, 1H,Ph), 7.07 (d, 1H, J = 7.3 Hz, Ph), 7.05 (d, 1H, 
J = 7.3 Hz, Ph), 5.84(s, 1H, benzyl-H), 3.34 (s, 6H, 2CH3), 
3.32 (s, 6H, 2CH3), 3.02 (q, 4H, J  =  7.3  Hz, CH2CH3), 
1.27 (t, 6H, J = 7.3 Hz, CH2CH3); 13C-NMR (100 MHz, 
CDCl3): δ  =  165.2, 164.4, 151.7, 144.7, 129.7,129.6, 
128.7, 125.3, 91.5, 42.1, 34.4, 28.9, 28.7, 11.5; Anal. for 
C23H30BrN5O6; Calcd: C, 50.01; H, 5.47; Br, 14.46; N, 
12.68; Found: C, 50.03; H, 5.48; Br, 14.47; N, 12.71; LC/
MS (ESI): m/z = 552[M]+.
A suitable crystal for X-ray diffraction analysis was 
obtained from DCM/Et2O after 24  h. CCDC-1001799 





4f; a yellow powder; m.p.: 180  °C; (88  %, 1.3  g, 
2.64 mmol); IR (KBr, cm−1): 3458, 3200, 2980, 2904, 1677, 
1620, 1572, 1511, 1438, 1343, 1254;1H-NMR (400 MHz, 
CDCl3): δ17.62 (s, 1H, OH), 7.31 (d, 2H, J = 8.8 Hz, Ph), 
6.99 (d, 2H, J = 8.8 Hz, Ph), 5.79(s, 1H, benzyl-H), 3.33 
(s, 12H, 4CH3), 3.03 (q, 4H, J = 7.3 Hz, CH2CH3), 1.27 (t, 
6H, J = 7.3 Hz, CH2CH3); 13C-NMR (100 MHz, CDCl3): 
δ =  165.3, 164.4, 151.7, 141.1, 131.2, 128.5, 119.3, 91.7, 
42.1, 34.2, 28.9, 28.7, 11.5; Anal. for C23H31N5O7; Calcd: 
C, 56.43; H, 6.38; N, 14.31; Found: C, 56.44; H, 6.36; N, 




4g; colorless needle materials; m.p.: 152 °C; (97 %, 1.41 g, 
2.91 mmol). IR (KBr, cm−1): 3455, 3210, 2984, 2820, 1560, 
1449, 1359; 1H-NMR (400  MHz, CDCl3): δ17.64 (s, 1H, 
OH), 6.99–6.96 (m, 4H, Ph), 5.80(s, 1H, benzyl-H), 3.32 
(s, 12H, 4CH3), 3.03 (q, 4H, J =  7.3  Hz, CH2CH3), 2.25 
(s, 3H, CH3), 1.28 (t, 6H, J = 7.3 Hz, CH2CH3); 13C-NMR 
(100 MHz, CDCl3): δ = 165.3, 164.3, 151.8, 138.6, 134.8, 
128.9, 126.3, 92.1, 42.0, 34.2, 28.9, 28.6, 21.0, 11.4; Anal. 
for C24H35N5O6; Calcd: C, 59.12; H, 6.82; N, 14.36; Found: 
C,59.13; H, 6.81; N, 14.35; LC/MS (ESI): m/z = 487[M]+.
A suitable crystal for X-ray diffraction analysis was 
obtained from DCM/Et2O after 24  h. CCDC-957025 





4h; beige powder; m.p.: 146 °C; (94 %, 1.47 g, 2.82 mmol). 
IR (KBr, cm−1): 3454, 3200, 2967, 1668, 1585, 1438, 
1250;1H-NMR (400  MHz, CDCl3): δ17.33 (s, 1H, 
OH), 8.10 (d, 2H, J =  8.8  Hz, naphthyl-H), 7.99 (d, 2H, 
J = 8.8 Hz, naphthyl-H), 7.92 (d, 2H, J = 8.8 Hz, naph-
thyl-H), 7.90 (d, 2H, J = 8.8 Hz, naphthyl-H), 7.84 (d, 2H, 
J = 8.8 Hz, naphthyl-H), 7.68–7.38 (m, 3H,naphthyl-H), 
6.37(s, 1H, benzyl-H), 3.39 (s, 12H, 4CH3), 3.01 (q, 4H, 
J = 7.3 Hz, CH2CH3), 1.30 (t, 6H, J = 7.3 Hz, CH2CH3); 
13C-NMR (100  MHz, CDCl3): δ  =  164.9, 151.7, 136.8, 
135.3, 134.3, 131.5, 129.1, 128.5, 127.0, 125.2 124.9, 123.8, 
93.2, 41.8, 33.2, 28.8, 11.4; Anal. for C27H33N5O6; Calcd: 
C, 61.94; H, 6.35; N, 13.38; Found: C, 61.95; H, 6.34; N, 




4i; white powder; m.p.: 205 C; (95 %; 1.22 g, 2.85 mmol); 
IR (KBr, cm−1): 3459, 3120, 2978, 2811, 1689, 1612, 1325, 
1252; 1H-NMR (400  MHz, DMSO-d6): δ17.18 (s, 1H, 
OH), 10.09 (bs, 4H, NH), 6.93 (m, 4H, Ph), 5.90(s, 1H, 
benzyl-H), 2.79 (q, 4H, J  =  7.3  Hz, CH2CH3), 2.20 (s, 
3H, CH3), 1.07 (t, 6H, J =  7.3  Hz, CH2CH3); 13C-NMR 
(100  MHz, DMSO-d6): δ  =  164.8, 164.1, 151.3, 142.1, 
133.5, 128.5, 127.1, 91.6, 42.6, 30.6, 21.1, 13.0; Anal. for 
C20H25N5O6; Calcd: C, 55.68; H, 5.84; N, 16.23; Found: C, 
55.67; H, 5.83; N, 16.22; LC/MS (ESI): m/z = 431[M]+.




4j; a white powder; m.p.: 221 °C; (95 %, 1.28 g, 2.85 mmol); 
IR (KBr, cm−1): 3435, 3185, 2978, 2830, 1677, 1548, 1448, 
1345, 1250;1H-NMR (400  MHz, DMSO-d6): δ17.17 (s, 
1H, OH), 10.00 (bs, 4H, NH), 7.18 (m, 4H, Ph), 5.93(s, 1H, 
benzyl-H), 2.88 (q, 4H, J = 7.3 Hz, CH2CH3), 1.12 (t, 6H, 
J =  7.3  Hz, CH2CH3); 13C-NMR (100  MHz, DMSO-d6): 
δ =  164.7, 164.0, 151.2, 144.6, 133.5, 129.9, 129.1, 127.8, 
91.3, 42.1, 30.7, 11.8; Anal. for C19H22ClN5O6; Calcd C, 
50.50; H, 4.91; Cl, 7.85; N, 15.50; Found: C, 50.51; H, 4.90; 




4k; a beige powder; m.p.: 195  °C; (91  %, 1.22  g, 
2.73 mmol); IR (KBr, cm−1): 3449, 3190, 2991, 2835, 1688, 
1592, 1505, 1383, 1247;1H-NMR (400  MHz, DMSO-
d6): δ17.26 (s, 1H, OH), 9.99 (bs, 4H, NH), 6.92 (d, 2H, 
J = 8.0 Hz, Ph), 6.72 (d, 2H, J = 8.0 Hz, Ph), 5.88(s, 1H, 
benzyl-H), 2.90 (q, 4H, J  =  7.3  Hz, CH2CH3), 1.14 (t, 
6H, J = 7.3 Hz, CH2CH3); 13C-NMR (100 MHz, DMSO-
d6): δ  =  164.6, 164.0, 157.0, 151.2, 137.2, 132.4, 115.1, 
91.7, 55.4, 42.1, 30.7, 11.6; Anal. for C20H25N5O7; Calcd 
C, 53.69; H, 5.63; N, 15.65; Found: C, 53.69; H, 5.63; N, 




4 l; a beige powder, m.p.: 192 °C; (93 %, 1.3 g, 2.79 mmol); 
IR (KBr, cm−1): 3459, 3208, 2994, 1677, 1579, 1448, 
1386, 1354;1H-NMR (400  MHz, DMSO-d6): δ16.92 (s, 
1H, OH), 10.41 (bs, 4H, NH), 8.13 (d, 1H, J  =  8.8  Hz, 
naphthyl), 7.81(d, 1H, J  =  8.8  Hz, naphthyl), 7.63 (d, 
1H, J =  8.8 Hz, naphthyl), 7.38–7.32 (m, 4H, naphthyl), 
6.46(s, 1H, benzyl-H), 2.79 (q, 4H, J = 7.3 Hz, CH2CH3), 
1.08 (t, 6H, J = 7.3 Hz, CH2CH3); 13C-NMR (100 MHz, 
DMSO-d6): δ  =  164.9, 151.1,141.5, 135.8, 134.0,132.4, 
129.3, 128.7, 126.0,125.8, 125.5, 125.2, 124.9, 123.8, 92.3, 
42.5, 29.7, 12.7; Anal. for C23H25N5O6; Calcd C, 59.09; H, 






4m; colorless crystalline material; m.p: 159  °C; (98  %, 
671  mg, 1.47  mmol). IR (KBr, cm−1): 3150, 2959, 1667, 
1617, 1585, 1422, 1256, 1227;1H NMR (400 MHz, CDCl3): 
δ 15.28 (s, 1H, OH), 7.17–7.04(m, 5H, Ph), 5.85 (s, 1H, 
benzyl-H), 3.29 (s, 12H, 4CH3), 2.96(q, 4H, J =  7.3  Hz, 
CH2CH3), 2.42 (d, 2H, J  =  5.1  Hz, CH2), 2.29 (m, 2H, 
CH2), 1.24(t, 6H, J = 7.3 Hz, CH2CH3), 1.14(s, 3H, CH3), 
1.05(s, 3H, CH3); 13C NMR (100 MHz, CDCl3): δ = 192.5, 
180.8, 152.5, 142.5, 128.0, 126.7, 125.1, 116.3, 90.9, 51.4, 
45.9, 42.2, 33.0, 31.5, 29.6, 28.4, 27.6, 11.4; Anal. for 
C25H35N3O5; calcd: C, 65.62; H, 7.71; N, 9.18;Found: C, 
65.61; H, 7.73; N, 9.20; LC/MS (ESI): m/z = 457 [M]+.
A suitable crystal for X-ray diffraction analysis was 
obtained from CHCl3/Et2O after 24  h. CCDC- 933624 




din‑4‑olate diethylaminium salt 4n
4n; oily material (97  %; 685  mg, 1.45  mmol). IR (KBr, 
cm−1): 3150, 2954, 2867, 1675, 1580, 1508, 1447, 1380, 
1256, 1145;1H NMR (400  MHz, CDCl3): δ 15.25 (s, 1H, 
OH), 7.00–6.93(m, 4H, Ph), 5.84 (s, 1H, benzyl-H), 3.28 
(s, 12H, 4CH3), 2.90(q, 4H, J  =  7.3  Hz, CH2CH3), 2.30 
(d, 4H, J =  5.1  Hz, CH2), 2.22 (s, 3H, CH3), 1.20(t, 6H, 
J = 7.3 Hz, CH2CH3), 1.16(s, 3H, CH3), 1.04(s, 3H, CH3); 
13C NMR (100  MHz, CDCl3): δ  =  196.5, 180.1, 152.8, 
140.5, 134.2, 129.8, 128.7, 126.8, 126.7, 115.6, 91.0, 51.4, 
45.9, 42.5, 32.6, 31.5, 29.6, 28.4, 27.6, 20.9, 11.9; Anal. for 
C26H37N3O5; calcd: C, 66.22; H, 7.91; N, 8.91;Found: C, 





4o; an oily material (92 %; 672 mg, 1.38 mmol). IR (KBr, 
cm−1): 3047, 2953, 2866, 2499, 1679, 1577, 1510, 1427, 
1373, 1255, 1214;1H NMR (400  MHz, CDCl3): δ 15.26 
(s, 1H, OH), 6.98(d, 2H, J  =  8.0  Hz, Ph), 6.72(d, 2H, 
J = 8.0 Hz, Ph), 5.69 (s, 1H, benzyl-H), 3.71 (s, 3H, CH3), 
3.29 (s, 12H, 4CH3), 2.87(q, 4H, J  =  7.3  Hz, CH2CH3), 
2.31 (d, 4H, J  =  5.1  Hz, CH2), 1.19(t, 6H, J  =  7.3  Hz, 
CH2CH3), 1.12(s, 3H, CH3), 1.03(s, 3H, CH3); 13C NMR 
(100 MHz, CDCl3): δ = 195.1, 187.2, 157.1, 134.5, 133.9, 
127.8, 127.6, 115.6, 113.4, 55.2, 42.6, 31.5, 31.1, 27.9, 
12.2; Anal. for C26H37N3O6; calcd: C, 64.05; H, 7.65; 




rahydropyrimidin‑4‑olate diethylaminium salt 4p
4p; oily material (97  %; 715  mg, 1.45  mmol). IR (KBr, 
cm−1): 3151, 2955, 2868, 2497, 1675, 1580, 1481, 1444, 
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1379, 1258, 1206;1H NMR (400 MHz, CDCl3): δ 15.02 (s, 
1H, OH), 7.12–6.95(m, 4H, Ph), 5.87 (s, 1H, benzyl-H), 
3.30 (s, 12H, 4CH3), 2.90(q, 4H, J  =  7.3  Hz, CH2CH3), 
2.38 (s, 4H, CH2), 1.20(t, 6H, J = 7.3 Hz, CH2CH3), 1.16(s, 
3H, CH3), 1.04(s, 3H, CH3); 13C NMR (100 MHz, CDCl3): 
δ = 198.1, 181.0, 152.5, 141.5, 130.6, 128.3, 128.2, 128.0, 
127.9, 115.2, 90.7, 65.9, 49.8, 42.3, 32.4, 31.5, 31.2, 29.6, 
28.4, 27.6, 15.3, 11.4; Anal. for C25H34ClN3O5; calcd: C, 
61.03; H, 6.97; Cl, 7.21; N, 8.54;Found: C, 61.06; H, 7.00; 
Cl, 7.18; N, 8.57; LC/MS (ESI): m/z = 492 [M]+.
5‑((4‑Bromophenyl)(2‑hydroxy‑4,4‑dimethyl‑6‑oxocy‑
clohex‑1‑en‑1‑yl)methyl)‑1,3‑dimethyl‑2,6‑dioxo‑1,2,3,6‑tet‑
rahydropyrimidin‑4‑olate diethylaminium salt 4q
4q; an oily material (95 %, 761 mg, 1.42 mmol). IR (KBr, 
cm−1): 3155, 2955, 2867, 2500, 1674, 1579, 1430, 1376, 
1204;1H NMR (400  MHz, CDCl3): δ 15.20 (s, 1H, OH), 
7.34 (d, 2H, J = 8.0 Hz, Ph), 6.98 (d, 2H, J = 8.0 Hz, Ph), 
5.79 (s, 1H, benzyl-H), 3.27 (s, 12H, 4CH3), 2.99(q, 4H, 
J  =  7.3  Hz, CH2CH3), 2.40 (d, 2H, J  =  5.1  Hz, CH2), 
2.28(m, 2H, CH2), 1.29(t, 6H, J = 7.3 Hz, CH2CH3), 1.18(s, 
3H, CH3), 1.04(s, 3H, CH3); 13C NMR (100 MHz, CDCl3): 
δ = 199.1, 191.2, 164.8, 152.4, 142.8, 132.5, 131.0, 129.9, 
128.7, 128.6, 118.9, 115.9, 90.6, 51.2, 45.8, 42.3, 32.7, 31.5, 
29.5, 28.5, 28.3, 27.6, 11.4; Anal. for C25H34BrN3O5; calcd: 
C, 55.97; H, 6.39; Br, 14.89; N, 7.83;Found: C, 56.00; H, 
6.40; Br, 14.86; N, 7.82; LC/MS (ESI): m/z = 536 [M]+.
5‑((3‑Bromophenyl)(2‑hydroxy‑4,4‑dimethyl‑6‑oxocy‑
clohex‑1‑en‑1‑yl)methyl)‑1,3‑dimethyl‑2,6‑dioxo‑1,2,3,6‑tet‑
rahydropyrimidin‑4‑olate diethylaminium salt 4r
4r; oily material (93  %, 745  mg, 1.39  mmol). IR (KBr, 
cm−1): 3050, 2955, 2868, 2500, 1675, 1581, 1444, 1378, 
1255, 1205; 1H NMR (400 MHz, CDCl3): δ 15.63 (s, 1H, 
OH), 7.22 (d, 1H, J = 7.3 Hz, Ph), 7.19 (s, 1H, Ph), 7.07 
(d, 1H, J = 7.3 Hz, Ph), 7.05 (d, 1H, J = 7.3 Hz, Ph), 5.84 
(s, 1H, benzyl-H), 3.34(s, 6H, 2CH3), 3.32(s, 6H, 2CH3), 
2.98(q, 4H, J = 7.3 Hz, CH2CH3), 2.31 (d, 4H, J = 5.1 Hz, 
CH2), 1.24(t, 6H, J = 7.3 Hz, CH2CH3), 1.12(s, 3H, CH3), 
1.03(s, 3H, CH3); 13C NMR (100 MHz, CDCl3): δ = 190.8, 
186.4, 165.2, 164.4, 151.7, 144.7, 129.7,129.6, 128.7, 125.3, 
91.5, 42.1, 34.4, 28.9, 28.7, 11.5; Anal. for C25H34BrN3O5; 
calcd: C, 55.97; H, 6.39; Br, 14.89; N, 7.83;Found: C, 56.01; 
H, 6.41; Br, 14.86; N, 7.84; LC/MS (ESI): m/z = 536 [M]+.
5‑((2‑Hydroxy‑4,4‑dimethyl‑6‑oxocyclohex‑1‑en‑1‑yl)
(1‑nitrophenyl)methyl)‑1,3‑dimethyl‑2,6‑dioxo‑1,2,3,6‑tet‑
rahydropyrimidin‑4‑olate diethylaminium salt 4s
4s; a beige material; m.p: 146  °C; (92  %, 690  mg, 
1.37 mmol). IR (KBr, cm−1): 3054, 2953, 2865, 2500, 1673, 
1580, 1510, 1427, 1373, 1255, 1214;1H NMR (400 MHz, 
CDCl3): δ 15.33 (s, 1H, OH), 7.01-7.35 (m, 3H, Ph), 
5.65 (s, 1H, benzyl-H), 3.70 (s, 12H, 4CH3), 2.89(q, 4H, 
J  =  7.3  Hz, CH2CH3), 2.30(d, 4H, J  =  14.7  Hz, CH2), 
1.15(t, 6H, J = 7.3 Hz, CH2CH3), 1.10(s, 3H, CH3), 1.00(s, 
3H, CH3); 13C NMR (100 MHz, CDCl3): δ = 161.6, 153.2, 
145.5, 141.6, 129.1, 128.2, 127.8, 125.8, 88.5, 49.1, 41.9, 
27.5, 11.5; Anal. for C25H34N4O7; calcd: C, 59.75; H, 6.82; 




oxo‑1,2,3,6‑tetrahydropyrimidin‑4‑olate diethylaminium salt 
4t
4t; a beige material; m.p: 165  °C; (73  %, 550  mg, 
1.1 mmol). IR (KBr, cm−1): 3055, 2950, 2865, 2500, 1669, 
1580, 1510, 1427, 1373, 1255, 1214;1H NMR (400 MHz, 
CDCl3): δ 15.33 (s, 1H, OH), 7.02 (d, 2H, J  =  8.0  Hz, 
Ph), 6.75 (d, 2H, J  =  8.8  Hz, Ph), 5.69 (s, 1H, benzyl-
H), 3.70 (s, 12H, 4CH3), 3.01 (s, 6H, N(CH3)2), 2.89(q, 
4H, J = 7.3 Hz, CH2CH3), 2.31(d,4H, J = 14.7 Hz, CH2), 
1.15(t, 6H, J = 7.3 Hz, CH2CH3), 1.12(s, 3H, CH3), 1.00(s, 
3H, CH3); 13C NMR (100 MHz, CDCl3): δ = 161.6, 153.2, 
145.5, 141.6, 129.1, 128.2, 127.8, 125.8, 88.5, 49.1, 41.9, 
41.8, 27.5, 11.5; Anal. for C27H39N4O5; calcd: C, 64.91; H, 




oxo‑1,2,3,6‑tetrahydropyrimidin‑4‑olate diethylaminium salt 
4v
4v; a white solid material; m.p: 162  °C; (91  %, 645  mg, 
1.36  mmol). IR (KBr, cm−1): 23097, 2939, 2884, 2828, 
2498, 1747, 1574, 1530, 1506, 1466, 1384, 1241;1H NMR 
(400 MHz, DMSO-d6): δ 14.52 (s, 1H, OH), 8.50 (brs, 1H, 
OH), 6.76(d, 2H, J = 8.0 Hz, Ph), 6.50(d, 2H, J = 8.0 Hz, 
Ph), 6.04(s, 1H, benzyl-H), 3.07 (s, 12H, 2CH3), 3.14(q, 
4H, J = 7.3 Hz, CH2CH3), 2.92 (q, 4H, J = 13.9 Hz, CH2), 
206 (s, 4H, CH2), 1.12(t, 6H, J = 7.3 Hz, CH2CH3), 0.98(s, 
3H, CH3); 13C NMR (100  MHz, DMSO-d6): δ  =  198.0, 
188.5, 154.1, 136.6, 128.3, 115.3, 114.3, 90.1, 50.9, 45.5, 
42.1, 31.6, 30.7, 29.7, 11.7; Anal. for C25H35N3O6; calcd: 
C, 63.41; H, 7.45; N, 8.87;Found: C, 63.40; H, 7.43; N, 
8.85; LC/MS (ESI): m/z = 473 [M]+.
4‑((6‑hydroxy‑1,3‑dimethyl‑2,4‑dioxo‑1,2,3,4‑tetrahy‑
dropyrimidin‑5‑yl)(2‑hydroxy‑4,4‑dimethyl‑6‑oxocy‑
clohex‑1‑en‑1‑yl)methyl)benzaldehyde diethylaminium salt 
4x
4x; as solid (1.26  g, 90  %). IR (cm−1): 3156, 2950, 2872, 
1678, 1590, 1508, 1375, 1256, 1232, 1167; 1H-NMR 
(CDCl3, 400  MHz): 14.16 (s, 1H, OH), 9.80 (s, 1H, 
CHO), 8.01 (brs, 2H, NH), 6.98 (d, 2H, J = 7.3 Hz, Ph), 
6.75 (d, 2H, J = 7.3 Hz, Ph), 5.61(s, 1H, benzyl-H), 3.73 
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(s, 6H, CH3), 2.92 (q, 4H, J = 7.3 Hz, CH2CH3), 2.31 (m, 
4H, 2CH2), 1.26(t, 6H, J = 7.3 Hz, CH2CH3), 1.05(s, 3H, 
CH3), 1.00(s, 3H, CH3); 13C-NMR (100  MHz, CDCl3): 
δ  =  193.0, 188.1, 165.0, 157.2, 127.8, 115.7,113.8, 91.6, 
55.2, 48.8, 48.6, 42.4, 31.5, 29.4, 27.7, 11.7; Anal. for 
C26H35N3O6; Calcd: C, 64.31; H, 7.27; N, 8.65; Found:C, 
64.30; H, 7.26; N, 8.63; LC/MS (ESI): m/z = 485.57 [M]+.
5‑((2,4‑Dichlorophenyl)(2‑hydroxy‑4,4‑dimethyl‑6‑oxocy‑
clohex‑1‑en‑1‑yl)methyl)‑1,3‑dimethyl‑2,6‑dioxo‑1,2,3,6‑tet‑
rahydropyrimidin‑4‑olate diethylaminium salt 4w
4w; a beige solid material; m.p: 164  °C; (90  %, 710  mg, 
1.35 mmol). IR (KBr, cm−1): 3059, 2995, 2867, 2114, 1741, 
1658, 1591, 1463, 1429, 1370, 1341, 1256, 12011H-NMR 
(400  MHz, CDCl3): δ 14.80 (s, 1H, OH), 7.29 (d, 1H, 
J = 8.0 Hz, Ph), 7.19 (s, 1H, Ph), 7.12(d, 2H, J = 8.0 Hz, 
Ph), 5.76 (s, 1H, benzyl-H), 3.28 (s, 12H, 4CH3), 3.07(q, 
4H, J  =  7.3  Hz, CH2CH3), 2.37 (s, 2H, CH2), 2.27 (d, 
2H, J = 5.1 Hz, CH2), 1.34 (t, 6H, J = 7.3 Hz, CH2CH3), 
1.04(s, 3H, CH3), 1.01 (s, 3H, CH3); 13C NMR (100 MHz, 
CDCl3): δ = 199.1, 165.4, 164.4, 152.5, 139.8, 133.6, 131.7, 
131.2, 129.3, 126.4, 115.7, 89.8, 51.2, 45.7, 41.9, 32.4, 31.2, 
28.3, 28.2, 11.3; Anal. for C25H33Cl2N3O5; calcd: C, 57.04; 
H, 6.32; Cl, 13.47; N, 7.98;Found: C, 57.09; H, 6.31; Cl, 
13.44; N, 8.01; LC/MS (ESI): m/z = 526 [M]+.
5‑((2,6‑Dichlorophenyl)(2‑hydroxy‑4,4‑dimethyl‑6‑oxocy‑
clohex‑1‑en‑1‑yl)methyl)‑1,3‑dimethyl‑2,6‑dioxo‑1,2,3,6‑tet‑
rahydropyrimidin‑4‑olate diethylaminium salt 4y
4y an oily material (89 %, 702 mg, 1.33 mmol). IR (KBr, 
cm−1): 3048, 2955, 2869, 2728, 2494, 1676, 1575, 1428, 
1372, 1238, 1196;1H NMR (400  MHz, CDCl3): δ 14.80 
(s, 1H, OH), 7.36 (d, 2H, J  =  8.0  Hz, Ph), 7.29 (t, 1H, 
J = 8.0 Hz, Ph), 7.12(d, 2H, J = 8.0 Hz, Ph), 5.98 (s, 1H, 
benzyl-H), 3.26 (s, 12H, 4CH3), 2.92(q, 4H, J =  7.3  Hz, 
CH2CH3), 2.37 (s, 2H, CH2), 2.27 (d, 2H, J  =  5.1  Hz, 
CH2), 1.24(t, 6H, J = 7.3 Hz, CH2CH3), 1.094(s, 3H, CH3), 
1.04(s, 3H, CH3); 13C NMR (100 MHz, CDCl3): δ = 192.8, 
188.9, 165.3, 164.3, 152.5, 149.7, 137.4, 131.5, 129.8, 
126.5, 124.2, 115.5, 114.7, 89.9, 53.5, 41.4, 31.9, 28.7, 28.2, 
11.4; Anal. for C25H33Cl2N3O5; calcd: C, 57.04; H, 6.32; 
Cl, 13.47; N, 7.98; Found: C, 57.08; H, 6.30; Cl, 13.45; N, 
8.00; LC/MS (ESI): m/z = 526 [M]+.
5‑((2‑Hydroxy‑4,4‑dimethyl‑6‑oxocyclohex‑1‑en‑1‑yl)
(naphthalen‑2‑yl)methyl)‑1,3‑dimethyl‑2,6‑dioxo‑1,2,3,6‑tet‑
rahydropyrimidin‑4‑olate diethylaminium salt 4z
4z; a white solid material; m.p: 170  °C; (94  %, 715  mg, 
1.41  mmol). IR (KBr, cm−1): 2994, 2948, 2866, 2506, 
1742, 1651, 1603, 1570, 1526, 1473, 1431, 1362, 1245;1H 
NMR (400  MHz, CDCl3): δ 14.26 (s, 1H, OH), 7.46–
7.22 (m, 7H, naphthyl), 6.20 (s, 1H, benzyl-H), 3.26 (s, 
6H, 2CH3), 3.23 (s, 6H, 2CH3), 3.14(q, 4H, J =  7.3  Hz, 
CH2CH3), 2.41 (q, 4H, J  =  5.1  Hz, CH2), 2.23 (s, 2H, 
CH2), 1.37(t, 6H, J  =  7.3  Hz, CH2CH3), 1.07(s, 3H, 
CH3), 1.01(s, 3H, CH3); 13C NMR (100  MHz, CDCl3): 
δ = 199.0, 180.5, 165.3, 164.3, 152.5, 149.7, 136.8, 131.5, 
129.9, 126.5, 124.2, 115.5, 114.7, 89.9, 50.9, 45.5, 41.7, 
31.3, 30.7, 28.2, 11.1; Anal. for C29H37N3O5; calcd: C, 
68.62; H, 7.35; N, 8.28; Found: C, 68.65; H, 7.34; N, 8.30; 




5a; as solid (1.26 g, 95 %). IR (cm−1): 2955 (s), 1586 (s), 
1382 (s), 776 (s), 576 (s), 480 (s); 1H-NMR (CDCl3, 
400 MHz) δ 13.91 (s, OH), 8.25 (bs, 1H. NH2), 7.01–7.21 
(m, 5H. ArH), 5.74 (s, 1H, PhCH), 2.84 (q, J  =  6.6  Hz, 
4H, NHCH2CH3), 2.31 (s, 8H, CH2  +  COCH2), 1.18 
(t, J  =  6.6  Hz, 6H, NHCH2CH3), 0.95–1.14 (m, 12H, 
CH3);13C-NMR (CDCl3, 100 MHz): δ 199.1, 179.3, 142.4, 
128.0, 126.8, 125.2, 115.5, 50.6, 45.9, 42.3, 34.2, 32.0, 11.4; 
Anal. Calcd.for C27H37NO4: C, 73.36; H, 8.98; N, 3.07; O, 




late diethylaminium salt 5b
3c; as solid (92 %, 1.31 g). IR (cm−1): 2956 (s), 1706 (s), 
1573 (s), 1486 (s), 1382 (s), 1263 (s), 732 (s), 605 (s), 485 
(s); 1H-NMR (CDCl3, 400  MHz) δ 13.59 (s, OH), 8.51 
(bs, 2H. NH2), 6.89–7.21 (m, 4H. ArH), 5.70 (s, 1H, 
PhCH), 2.90 (q, J = 7.3 Hz, 4H, NHCH2CH3), 2.30 (s, 8H, 
CH2 + COCH2), 1.21 (t, J = 7.3 Hz, 6H, NH2CH2CH3), 
0.91–1.16 (m, 12H, CH3); 13C-NMR (CDCl3, 100 MHz): 
δ197.3, 188.6, 139.5, 130.8, 128.3, 128.1, 115.2, 49.7, 44.9, 
42.2, 34.3, 33.1, 31.5, 11.3; Anal. Calcd. forC27H38ClNO4: 
C, 68.23; H, 8.19; N, 2.97; O, 13.34; Found: C, 68.12; H, 




5c; as solid (93 %, 1.2 g). IR (cm−1): 2957 (s), 1571 (s), 1483 
(s), 1383 (s), 1267 (s), 739 (s), 488 (s); 1H-NMR (CDCl3, 
400 MHz) δ 13.73 (s, OH), 7.83 (bs, 2H. NH2), 6.91–7.05 
(m, 4H. ArH), 5.73 (s, 1H, PhCH), 2.84 (q, J = 7.3 Hz, 4H, 
NHCH2CH3), 2.31 (s, 8H, CH2 +  COCH2), 2.23 (s, 3H, 
PhCH3), 1.18 (t, J = 7.3 Hz, 6H, NH2CH2CH3), 0.94–1.16 
(m, 12H, CH3), 13C-NMR (CDCl3, 100  MHz): δ195.8, 
187.3, 144.4, 134.0, 128.6, 126.8, 115.6, 51.8, 46.1, 42.7, 
34.9, 32.7, 31.4, 20.9,12.4; Anal. Calcd. forC28H41NO4: C, 
73.79; H, 9.14; N, 3.09; O, 13.91; Found: C, 73.81; H, 9.07; 
N, 3.07; O, 14.05; LC/MS (ESI): m/z = 455.30 [M]+.




5d; as solid (91 %, 1.24 g). IR (cm−1): 2952 (s), 1572 (s), 
1483 (s), 1381 (s), 1227 (s), 1143 (s), 787 (s), 463 (s); 1H-
NMR (CDCl3, 400  MHz) δ 13.78 (s, OH), 7.85 (bs, 2H. 
NH2), 6.88–7.03 (m, 4H. ArH), 5.71 (s, 1H, PhCH), 
2.91 (q, J  =  7.4  Hz, 4H, NHCH2CH3), 2.38 (s, 8H, 
CH2 + COCH2), 2.28 (s, 3H, PhCH3), 1.16 (t, J = 7.4 Hz, 
6H, NH2CH2CH3), 0.91–1.12 (m, 12H, CH3); 13C-NMR 
(CDCl3, 100  MHz): δ195.9, 187.5, 144.7, 134.1, 128.4, 
126.9, 115.8, 51.9, 46.3, 42.6, 34.8, 32.8, 31.2, 20.6, 12.3; 
Anal. Calcd.for C28H41NO4: C, 73.85; H, 9.09; N, 3.13; O, 




clohex‑1‑enolate diethylaminium salt 5e
5e; as solid (89  %, 1.26  g). IR (cm−1): 3121 (s), 1668 (s), 
1614 (s), 1578 (s), 1446 (s), 778 (s), 608 (s), 457 (s); 1H-
NMR (CDCl3, 400  MHz) δ 14.67 (s, OH), 8.22 (bs, 2H. 
NH2), 6.97 (d, J = 7.4 Hz, 2H. ArH), 6.72 (d, J = 7.4 Hz, 
2H, ArH), 5.72 (s, 1H, PhCH), 3.72 (s, 3H, OCH3), 2.85 (q, 
J = 7.4 Hz, 4H, NHCH2CH3), 2.30 (s, 8H, CH2 + COCH2), 
1.20 (t, J = 7.4 Hz, 6H, NH2CH2CH3), 0.96–1.16 (m, 12H, 
CH3); 13C-NMR (CDCl3, 100 MHz): δ 194.1, 187.5, 157.6, 
133.1, 127.8, 115.7, 113.4, 55.2, 50.7, 45.3, 42.5, 34.1, 31.5, 
31.1,11.9; Anal. Calcd.for C28H41NO5: C, 71.19; H, 8.79; N, 
3.05; O, 17.11; Found: C, 71.31; H, 8.76; N, 2.97; O, 16.96; 
LC/MS (ESI): m/z = 471.30 [M]+.
2‑((2‑Hydroxy‑4,4‑dimethyl‑6‑oxocyclohex‑1‑en‑1‑yl)
(4‑nitrophenyl)methyl)‑5,5‑dimethyl‑3‑oxocyclohex‑1‑eno‑
late diethylaminium salt 5f
5f; as solid (90  %, 1.26  g). IR (cm−1): 2872 (s), 1582 (s), 
1510 (s), 1466 (s), 1384 (s), 1339 (s), 757 (s), 487 (s); 1H-
NMR (CDCl3, 400  MHz) δ15.12 (s, OH), 8.32(bs, 2H. 
NH2), 8.01 (m, J = 8.8 Hz, 2H.ArH), 7.21 (d, J = 8.8 Hz, 
2H, ArH), 5.92 (s, 1H, PhCH), 2.94 (q, J =  7.3  Hz, 4H, 
NHCH2CH3), 2.29 (s, 8H, CH2  +  COCH2), 1.21 (t, 
J = 7.3 Hz, 6H, NH2CH2CH3), 0.91–1.06 (m, 12H, CH3); 
13C-NMR (CDCl3, 100 MHz): δ 194.9, 186.8, 151.9, 145.5, 
127.7, 123.2, 114.8, 50.3, 42.5, 45.2, 34.1, 32.2, 31.6, 11.4; 
Anal. Calcd. forC27H38N2O6: C, 66.74; H, 7.98; N, 5.55; O, 




late diethylaminium salt 5g
5g; as solid (91 %, 1.39 g). IR (cm−1): 2953 (s), 2869 (s), 
1711 (s), 1575 (s), 1497 (s), 1367 (s), 1220 (s), 776 (s), 448 
(s); 1H-NMR (CDCl3, 400 MHz) δ 14.78 (s, OH), 8.71 (bs, 
2H. NH2), 7.24(s, J  =  14.4  Hz, 1H, ArH), 7.16 (m, 1H, 
ArH), 6.95 (d, J = 14.4 Hz, 1H, ArH), 5.89 (s, 1H, PhCH), 
2.90 (q, J  =  7.4  Hz, 4H, NHCH2CH3), 2.19 (bs, 8H, 
CH2 + COCH2), 1.17 (t, J = 7.4 Hz, 6H, NH2CH2CH3), 
0.88–1.03 (bs, 12H, CH3); 13C-NMR (DMSO-d6, 
100  MHz): δ 198.3, 189.1, 139.1, 134.9, 128.2, 125.9, 
114.2, 51.1, 47.6, 42.5, 34.3, 31.8, 30.3, 11.9; Anal. Calcd.
for C27H37Cl2NO4: C, 63.46; H, 7.55; N, 2.43; O, 12.91; 




late diethylaminium salt 5h
5h; as solid (90 %, 1.26 g). IR (cm−1): 2872 (s), 1582 (s), 
1510 (s), 1466 (s), 1384 (s), 1339 (s), 757 (s), 487 (s); 1H-
NMR (CDCl3, 400  MHz) δ 15.12 (s, OH), 8.32(bs, 2H. 
NH2), 8.01 (m, J = 8.8 Hz, 2H.ArH), 7.21 (d, J = 8.80 Hz, 
2H, ArH), 5.92 (s, 1H, PhCH), 2.94 (q, J =  7.3  Hz, 4H, 
NHCH2CH3), 2.29 (s, 8H, CH2  +  COCH2), 1.21 (t, 
J = 7.3 Hz, 6H, NH2CH2CH3), 0.91–1.06 (m, 12H, CH3); 
13C-NMR (CDCl3, 100 MHz): δ194.9, 186.8, 151.9, 145.5, 
127.7, 123.2, 114.8, 50.3, 45.2, 42.5, 34.1, 32.2, 31.6, 11.4; 
Anal. Calcd. forC27H38N2O6: C, 66.74; H, 7.98; N, 5.55; O, 




late diethylaminium salt 5i
5i; as solid (87  %, 1.22  g). IR (cm−1): 3096 (s), 2938 (s), 
2869 (s), 1580 (s), 1539 (s), 1506 (s), 1384 (s), 1241 (s), 
1033 (s), 778 (s), 604 (s), 524 (s); 1H-NMR (CDCl3, 
400  MHz) δ 14.27 (s, OH), 8.74 (bs,2H. NH2), 7.10 (m, 
4H, ArH), 6.22 (s, 1H, PhCH), 2.03 (q, J =  7.3  Hz, 4H, 
NHCH2CH3), 2.20 (bs, 8H, CH2  +  COCH2), 1.29 (t, 
J = 7.3 Hz, 6H, NH2CH2CH3), 0.99 (bs, 12H, CH3);13C-
NMR (CDCl3, 100  MHz): δ 198.9, 181.9, 149.7, 137.4, 
131.3, 130.2, 125.9, 124.1, 114.5, 49.9, 44.8, 42.0, 33.6, 
31.4, 29.4, 11.2; Anal. Calcd. forC27H38N2O6: C, 66.94; H, 
7.87; N, 5.43; O, 19.96; Found: C, 66.64; H, 7.87; N, 5.76; 
O, 19.73; LC/MS (ESI): m/z = 468.27 [M]+.
2‑((4‑Formylphenyl)(2‑hydroxy‑4,4‑dimethyl‑6‑oxocy‑
clohex‑1‑en‑1‑yl)methyl)‑5,5‑dimethyl‑3‑oxocyclohex‑1‑eno‑
late diethylaminium salt 5j
5j; as solid (75  %, 1.01  g). IR (cm−1): 3150 (s), 1586 (s), 
1519 (s), 1469 (s), 1381 (s), 1339 (s), 779 (s), 495 (s); 
1H-NMR (DMSO-d6, 400  MHz) δ16.45 (s, OH), 8.39 
(bs, 2H. NH2), 6.78 (m, J =  8.04  Hz, 2H. ArH), 6.49 (d, 
J  =  8.04  Hz, 2H, ArH), 6.08 (s, 1H, PhCH), 3.00 (s, 
6H, N(CH3)2), 2.89 (q, J  =  7.32  Hz, 4H, NHCH2CH3), 
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2.10 (s, 8H, CH2  +  COCH2), 1.15 (t, J  =  7.32  Hz, 6H, 
NH2CH2CH3), 0.88–1.01 (m, 12H, CH3); 13C-NMR 
(DMSO-d6,100  MHz): δ196.1, 183.6, 154.1, 136.1, 
128.3, 115.3, 114.3,50.9,45.6, 42.0, 41.7, 34.2, 31.9, 29.8, 
11.8; Anal. Calcd.for C28H39NO5: C, 71.61; H, 8.37; N, 




clohex‑1‑enolate diethylaminium salt 5k
5k; as solid (88  %, 1.01  g). IR (cm−1): 3157 (s), 1584 
(s), 1519 (s), 1469 (s), 1381 (s), 1339 (s), 779 (s), 495 
(s); 1H-NMR (DMSO-d6, 400  MHz) δ 16.41 (s, OH), 
8.32 (bs, 2H. NH2), 6.75 (m, J  =  8.0  Hz, 2H. ArH), 
6.45 (d, J =  8.0  Hz, 2H, ArH), 6.04 (s, 1H, PhCH), 2.88 
(q, J  =  7.3  Hz, 4H, NHCH2CH3), 2.50 (s, 1H, PhOH), 
2.06 (s, 8H, CH2  +  COCH2), 1.12 (t, J  =  7.32  Hz, 6H, 
NH2CH2CH3), 0.85–0.97 (m, 12H, CH3); 13C-NMR 
(DMSO-d6, 100 MHz): δ 196.1, 183.6, 154.1, 136.1,128.3, 
115.3, 114.3, 50.9, 45.6, 42.0, 34.2, 31.9, 29.8, 11.8; Anal. 
Calcd.for C27H39NO5: C, 70.74; H, 8.89; N, 3.13; O, 17.61; 




din‑5‑yl)methyl)benzaldehyde diethylaminium salt 5l
5l; as white solid (88  %, 1.20  g). IR (cm−1): 3455, 3305, 
3000, 2910, 1677, 1582, 1510, 1466, 1384, 1339; 1H-
NMR (CDCl3, 400 MHz) 17.30 (s, 1H, OH), 9.90 (s, 1H, 
CHO), 8.23 (brs, 2H, NH), 7.56 (d, 2H, J = 8.0 Hz, Ph), 
7.11 (d, 2H, J = 8.0 Hz, Ph), 5.85(s, 1H, benzyl-H), 3.34 
(s, 12H, 4CH3), 3.03 (q, 4H, J = 7.3 Hz, CH2CH3), 1.25 (t, 
6H, J = 7.3 Hz, CH2CH3); 13C-NMR (100 MHz, CDCl3): 
δ = 192.1, 165.2, 164.1, 151.2, 150.0, 134.1, 129.5, 127.5, 
91.6, 42.2, 35.1, 29.0, 28.7, 11.5; Anal. for C22H27N5O7; 
Calcd: C, 55.81; H, 5.75; N, 14.79; Found:C, 55.83; H, 
5.76; N, 14.81; LC/MS (ESI): m/z = 473.48 [M]+.
5‑((4‑Chlorophenyl)(2‑hydroxy‑4,4‑dimethyl‑6‑oxocy‑
clohex‑1‑en‑1‑yl)methyl)‑2,6‑dioxo‑1,2,3,6‑tetrahydropyrimi‑
din‑4‑olate diethylaminium salt 5m
5m; an oily product (90  %, 625  mg, 1.35  mmol). IR 
(KBr, cm−1): 3049, 2954, 2865, 2499, 1738, 1699, 1590, 
1483, 1375, 1292, 1258, 1225, 1205;1H NMR (400 MHz, 
CDCl3): δ 13.32 (s, 1H, OH), 8.83 (brs, 2H, NH), 7.27(d, 
2H, J = 8.0 Hz, Ph), 7.00(d, 2H, J = 8.0 Hz, Ph), 5.89 (s, 
1H, benzyl-H), 2.88(q, 4H, J = 7.3 Hz, CH2CH3), 2.31 (d, 
4H, J = 5.1 Hz, CH2), 1.19(t, 6H, J = 7.3 Hz, CH2CH3), 
1.09(s, 3H, CH3), 1.03(s, 3H, CH3); 13C NMR (100 MHz, 
CDCl3): δ = 190.9, 141.0, 134.8, 131.0, 129.5, 128.3, 115.3, 
91.1, 47.1, 42.7, 31.6, 31.5, 29.1, 28.2, 27.8, 11.3; Anal. 
for C23H30ClN3O5; calcd: C, 59.54; H, 6.52; Cl, 7.64; N, 





5n; a white solid material; m.p: 215  °C; (93  %, 598  mg, 
1.39 mmol). IR (KBr, cm−1): 3027, 2948, 2867, 2156, 1683, 
1593, 1451, 1374, 1291, 1257, 11411H-NMR (400  MHz, 
CDCl3): δ 12.26 (s, 1H, OH), 9.31(brs, 2H, NH), 7.12(m, 
5H, Ph), 5.52 (s, 1H, benzyl-H), 2.99(q, 4H, J =  7.3  Hz, 
CH2CH3), 2.45 (d, 4H, J  =  5.1  Hz, CH2), 1.24(t, 6H, 
J = 7.3 Hz, CH2CH3), 1.09(s, 3H, CH3), 1.03(s, 3H, CH3); 
13C NMR (100  MHz, CDCl3): δ  =  198.5, 180.8, 152.5, 
142.5, 128.0, 126.7, 125.1, 116.3, 90.9, 51.4, 45.9, 42.2, 
33.0, 28.4, 27.6, 11.3; Anal. for C23H31N3O5; calcd: C, 




din‑4‑olate diethylaminium salt 5o
5o; a white solid material; m.p: 208  °C; (89  %, 678  mg, 
1.33  mmol); IR (KBr, cm−1): 3093, 2939, 2885, 2829, 
2551, 1746, 1686, 1576, 1506, 1466, 1416, 1268, 1241; 1H 
NMR (400 MHz, CDCl3): δ 13.31 (s, 1H, OH), 8.67 (brs, 
2H, NH), 7.05(m, 4H, Ph), 5.79 (s, 1H, benzyl-H), 2.79(q, 
4H, J = 7.3 Hz, CH2CH3), 2.35 (d, 4H, J = 5.1 Hz, CH2), 
1.21(t, 6H, J = 7.3 Hz, CH2CH3), 1.11(s, 3H, CH3), 1.03(s, 
3H, CH3); 13C NMR (100 MHz, CDCl3): δ = 198.5, 180.1, 
152.8, 140.5, 131.4, 130.7, 128.7, 128.6, 118.5, 115.6, 
91.0, 50.9, 42.8, 31.6, 31.5, 29.2, 28.3, 27.8, 11.3; Anal. 
for C23H30BrN3O5; calcd: C, 54.34; H, 5.95; Br, 15.72; N, 





5p; a white solid material; m.p: 213  °C; (91  %, 604  mg, 
1.36  mmol). IR (KBr, cm−1): 3150, 2955, 2867, 1690, 
1592, 1508, 1375, 1256, 1232, 1167;1H NMR (400 MHz, 
CDCl3): δ 13.31 (s, 1H, OH), 8.83 (brs, 2H, NH), 7.27(d, 
2H, J = 8.0 Hz, Ph), 7.00(d, 2H, J = 8.0 Hz, Ph), 5.88 (s, 
1H, benzyl-H), 2.83(q, 4H, J  =  7.3  Hz, CH2CH3), 2.31 
(d, 4H, J =  5.1  Hz, CH2), 2.23 (s, 3H, CH3), 1.19(t, 6H, 
J = 7.3 Hz, CH2CH3), 1.04(s, 3H, CH3), 1.02(s, 3H, CH3); 
13C NMR (100  MHz, CDCl3): δ  =  196.5, 180.1, 152.8, 
140.5, 131.4, 130.7, 128.7, 128.6, 118.5, 115.6, 91.0, 50.9, 
42.8, 31.6, 31.5, 29.2, 28.3, 27.8, 20.9, 11.3; Anal. for 
C24H33N3O5; calcd: C, 64.99; H, 7.50; N, 9.47;Found: C, 
64.95; H, 7.49; N, 9.50; LC/MS (ESI): m/z = 443 [M]+.
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2‑((4‑Formylphenyl)(6‑hydroxy‑2,4‑dioxo‑1,2,3,4‑tetrahydro‑
pyrimidin‑5‑yl)methyl)‑5,5‑dimethyl‑3‑oxocyclohex‑1‑eno‑
late diethylaminium salt 5q
5q; a white solid material; m.p: 205  °C; (87  %, 594  mg, 
1.3  mmol). IR (KBr, cm−1): 3145, 2950, 2870, 1677, 
1550, 1510, 1375, 1256, 1232, 1167; 1H NMR (400 MHz, 
CDCl3): δ 13.35 (s, 1H, OH), 9.92 (s, 1H, CHO), 8.80 
(brs, 2H, NH), 7.30(d, 2H, J  =  8.0  Hz, Ph), 7.05(d, 2H, 
J  =  8.0  Hz, Ph), 5.85 (s, 1H, benzyl-H), 2.89(q, 4H, 
J  =  7.3  Hz, CH2CH3), 2.30 (d, 4H, J  =  5.1  Hz, CH2), 
2.26(s, 3H, CH3), 1.22(t, 6H, J = 7.3 Hz, CH2CH3), 1.08(s, 
3H, CH3), 1.05(s, 3H, CH3); 13C NMR (100 MHz, CDCl3): 
δ  =  198, 181.3, 152.8, 140.5, 131.4, 130.7, 128.7, 128.6, 
118.5, 115.6, 91.0, 50.9, 42.8, 31.6, 31.5, 29.2, 28.3, 27.8, 
20.9, 11.3; Anal. for C24H31N3O6; calcd: C, 63.00; H, 6.83; 




rimidin‑4‑olate diethylaminium salt 5r
5r; an oily product (90  %, 646  mg, 1.35  mmol). IR 
(KBr, cm−1): 3049, 2948, 2863, 2725, 1685, 1594, 
1508, 1371, 1252, 1216; 1H NMR (400  MHz, CDCl3): 
δ 14.25 (s, 1H, OH), 7.46-7.22(m, 7H, naphthyl), 
6.21 (s, 1H, benzyl-H), 3.27 (s, 6H, 2CH3), 3.25 (s, 
6H, 2CH3), 3.14(q, 4H, J =  7.3  Hz, CH2CH3), 2.41 (q, 
4H, J  =  5.1  Hz, CH2), 2.23 (s, 2H, CH2), 1.37(t, 6H, 
J  =  7.3  Hz, CH2CH3), 1.07(s, 3H, CH3), 1.01(s, 3H, 
CH3); 13C NMR (100  MHz, CDCl3): δ =  199.1, 180.5, 
165.5, 164.2, 152.5, 149.7, 136.8, 131.5, 129.9, 126.5, 
124.2, 115.5, 114.7, 89.9, 50.9, 45.5, 41.7, 31.3, 30.7, 
28.2, 11.3; Anal. for C27H33N3O5; calcd: C, 67.62; H, 





5s; as solid (93  %, 1.33  g). IR (cm−1): 3053 (s), 2943 
(s), 2866 (s), 1688 (s), 1566 (s), 1511 (s), 1383 (s), 1241 
(s), 1035 (s), 774 (s), 482 (s), 554 (s); 1H-NMR (CDCl3, 
400  MHz) δ 1.01 (bs, 12H, CH3), 1.19 (t, J  =  7.3  Hz, 
6H, NH2CH2CH3), 2.29 (bs, 8H, CH2 +  COCH2), 2.88 
(q, J  =  7.3  Hz, 4H, NHCH2CH3), 6.32 (s, 1H, PhCH), 
7.55–7.64 (m, 2H, ArH), 7.69 (t, J = 7.4 Hz, 1H, ArH), 
7.91 (d, J = 8.8 Hz, 1H, ArH), 7.99 (d, J = 6.6 Hz, 1H, 
ArH), 8.10 (d, J = 8.1 Hz, 1H, ArH), 9.25 (d, J = 8.0 Hz, 
1H, ArH), 1039 (s,2H. NH2), 14.25 (s, OH); 13C-NMR 
(CDCl3, 100  MHz): δ 193.6, 182.8, 136.8, 135.4, 133.8, 
131.5, 124.7, 116.8, 50.5, 130.6, 128.6, 129.1, 127.0, 45.3, 
42.2, 33.9, 31.4, 29.8, 11.7; Anal. Calcd.for C30H39NO4: 
C, 75.83; H, 8.05; N, 3.03; O, 13.29; Found: C, 75.71; 
H, 8.23; N, 2.91; O, 13.40; LC/MS (ESI): m/z =  477.29 
[M]+.
Procedure for In vitro Urease Inhibiton Assay
Reaction mixture comprising of 25μL of enzyme (jack 
bean urease) (1 unit/well) solution and 55 μL of phos-
phate buffers (4  mM) containing 100  mM urea were 
incubated with 5 μL of test compounds dissolved in 
methanol (0.5  mM concentration) at 30  °C for 15  min 
in 96-well plates. Urease activity was determined by 
measuring ammonia production using the indophe-
nol method as described by Weather burn [30]. Briefly, 
45 μl each phenol reagent (1 % w/v phenol and 0.005 % 
w/v sodium nitroprussside) and 70  μL of alkali rea-
gent(0.5 % w/v NaOH and 0.1 % active chloride NaOCl) 
were added to each well. The increasing absorbance 
at 630  nm was measured afther 50  min, using a micro-
plate reader (Molecular Device, USA). All reactions were 
performed in triplicate in a final volume of 200 μL. The 
results (change in absorbance per min) were processed 
by using softMax Pro software (molecular Device, USA). 
The entire assays were performed at pH 6.8. Percent-
age inhibitions were calculated from the formula 100 −   
(ODtestwell/ODcontrol)  ×  100. Thiourea was used as the 
standard inhibitor of urease [31, 32].
Materials and methods for MD simulation and molecular 
docking studies
Receptor and ligand preparation
The crystal structure of helicobacter pylori (HP) urease 
in complex with acetohydroxamic acid, (PDB entry code 
1E9Y) was retrieved from the protein data bank [33]. All 
the water molecules were removed from the PDB crystal 
structure and hydrogen atoms were added. This structure 
was followed by energy minimization with amber99 force 
field (http://www.chempcomp.com) in the molecular 
operating environment (MOE) Software packages [34]. 
The three dimensional structure of the compounds were 
constructed via Builder module implemented in MOE. 
Subsequently all the compounds structures were mini-
mized by using MMFF94 force field [35] in MOE preced-
ing to molecular docking studies.
Protocol selection
Initially docking was performed for both the isomers i.e. 
keto and enol form. For docking purpose, default dock-
ing parameters of MOE is used such as Triangle Matcher 
Algorithm with two different rescoring functions. Lon-
don dG and GBVI/WSA dG were used to generate 30 
poses of each ligand and were saved in MOE database. 
Finally, docking results were analyzed by visualizing sev-
eral interactions of compounds within binding pocket of 
proteins.
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Molecular dynamic simulation
The keto and enol complexes were energy-minimized 
to eliminate possible steric strain up to 0.1 gradients by 
using AMBER99 force field. The relaxed complexes were 
then subjected to MD simulations using MOE 2013.0801 
software. Each complex was gradually simulated at 300 K 
for 100 ps, in order to simulate the physiological condi-
tions, system is allowed to maintain at physiological tem-
perature of 300 K. The temperature is attained gradually, 
to avoid protein destruction, over a period of 100  ps. 
Initially, protein is heated from 0 to 50 K, followed by its 
ramping to 100, 200 and finally 300  K and then equili-
brated at 300 K for even distribution of water molecules 
keeping protein molecule constrained. After equilibra-
tion step MD simulation was performed for 5 ns by using 
the Nose-Poincare-Anderson (NPA) method [36]. To 
make ensemble trajectories NVT ensemble was used.
The trajectory output files were saved after every 1 ps 
for future analysis. Equilibration was monitored by con-
vergence in terms of the temperature, energy, density and 
the RMSD (root-mean-squared deviations) of the back-




In our continued interest [30, 37–47] in the development 
of highly expedient methods for the synthesis of diverse 
heterocyclic compounds of biological importance via 
one-pot multi-component reactions (MCRs) and avoid-
ing organic solvents during the reactions in organic syn-
thesis leads to efficient, environmentally benign reagents, 
clean, and economical technology (Green Chemistry 
Concepts). In the present investigation, reaction of equi-
molar amounts of barbituric acid 1a,b dimedone 2 with 
aldehyde 3 in presence of aqueous diethylamine medium 
at RT afforded zwitterionic adducts 4a–z and 5a–s in 
quantitative yields by simple filtration (Scheme 1).
Biological activity
Thirty-two new derivatives of barbituric acid as 
zwitterionic adducts of diethyl ammonium salts 
having bis(6-hydroxy-1,3-dimethyl-2,4-dioxo-1,2,3,4- 
tetrahydropyrimidin-5-yl) (4a–h), bis-(6-hydroxypy-
rimidine-2,4(1H,3H)-dione) (4i–4l), (2-hydroxy-4,4- 
dimethyl-6-oxocyclohex-1-en-1-yl)-1,3-dimethyl-
2 ,6-dioxo-1 ,2 ,3 ,6- te trahydropyr imidin-4-olate 
(4m–4z), 4-((6-Hydroxy-1,3-dimethyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)(6-hydroxy-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)methyl) benzaldehyde (5l), 
(2-hydroxy-4,4-dimethyl-6-oxocyclohex-1-en-1-yl)
methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-olate 
(5m–5r) and twelve derivatives of dimedone as 
zwitterionic adducts of diethyl ammonium salts having 
bis-(2-hydroxy-4,4-dimethyl-6-oxocyclohex-1-en (5a–k 
and 5s) as basic nucleus were screened in vitro for their 
ureas enzyme inhibition potential against thiourea 
(IC50 = 21.2 ± 1.3 µM), as an standard tested compounds 
(Table 1).
Among barbituric acid zwitterionic adducts (4a–h) 
having bis(6-Hydroxy-1,3-dimethyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl) ring as basic nucleus, all 
ccompounds 4a, 4b, 4d, 4e, 4g and 4f showed IC50 val-
ues 39.3 ±  0.36, 34.4 ±  1.57, 31.6 ±  0.79, 27.5 ±  0.12, 
28.5  ±  0.41, and 40.3  ±  0.32  µM respectively, and 
were found to be the potent urease inhibitors except 
compounds 4c (IC50  =  54.2  ±  0.47  µM) and 4f 
(IC50 = 54.2 ± 0.83 µM), while compared with the stand-
ard compound thiourea (IC50 = 21.2 ± 1.3 µM).
Among the barbituric acid derived derivatives 
(4i–4l), having bis(6-hydroxypyrimidine-2,4(1H,3H)-
dione) as backbone, all tested compounds i.e. 4i 
(IC50 = 17.6 ± 0.23 µM), 4j (IC50 = 22.3 ± 0.73 µM), 4 k 
(IC50 = 25.8 ± 0.23 µM) and 4 l (IC50 = 22.7 ± 0.20 µM) 
were found to be potent inhibitors of urease enzyme. 
Methyl substituted phenyl ring containing compound 4i 
(IC50 = 17.6 ± 0.23 µM) was the most active candidate of 
the series.
Third series of the derivatives of barbituric acids having 
(2-Hydroxy-4,4-dimethyl-6-oxocyclohex-1-en-1-yl)-
1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-
4-olate ring as basic nucleus (4m–4z) were also evaluated 
for their urease enzyme inhibition. Compounds 4m 
(IC50 = 39.3 ± 0.79 µM), 4n (IC50 = 41.2 ± 0.58 µM), 4p 
(IC50 = 39.7 ± 0.70 µM), 4q (IC50 = 24.6 ± 0.42 µM), 4r 
(IC50 = 27.5 ± 0.19 µM), 4x (IC50 = 38.5 ± 0.28 µM), and 
4z (IC50 = 39.8 ± 1.38 µM) was found to be potent ure-
ase inhibitors against the standard thiourea.
Among fourth series of the derivatives of barbituric 
acid having (2-hydroxy-4,4-dimethyl-6-oxocyclohex-
1-en-1-yl)methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-
4-olate) ring as basic nucleus (5m–5r), compound 5n 
(IC50 = 23.7 ± 0.57 µM), 5o (IC50 = 34.6 ± 0.79 µM), 5p 
(IC50 = 27.4 ± 0.54 µM), and 5q (IC50 = 41.6 ± 0.41 µM), 
showed poetnt urease inhibiton. All other compounds 
found to be weak urease inhibitors.
Similarly dimedone derivatives, bis-(2-hydroxy-4,4- 
dimethyl-6-oxocyclohex-1-en) ring conatining com-
pounds 5a–s were also evaluated for their in  vitro ure-
ase enzyme inhibition potential. Compounds 5b (IC50 =   
29.7  ±  0.67  µM), 5e (IC50  =  39.8  ±  0.75  µM), and 5k 
(IC50 = 43.8 ± 0.33 µM), showed good enzyme inhibtion. 
All other compounds found to be significant to weak ure-
ase inhibitors (IC50 = 49.0 ± 0.55–210.1 ± 0.29 µM).
On the basis of the evaluated urease inhibition abilities 
of the above five different series of barbituric acid and 




























































































4n R1=R2=R4=H, R3= CH3
4o R1=R2=R4=H, R3= OCH3
4p R1=R2=R4=H, R3= Cl
4q R1=R2=R4=H, R3= Br
4r R1=R3=R4=H, R2= Br
4s R1=NO2, R2=R3= R4= H
4t R1=R2=R4=H, R3= NMe2
4v R1=R2=R4=H, R3= OH
4w R1=R3=Cl, R2=R4=H


































5b R1=R2=R4=H, R3= Cl
5c R1=R3= R4=H, R2=CH3
5d R1=R3=R4=CH3, R2=H
5e R1=R2=R4=H, R3= OCH3




5j R1=R2=R4=H, R3= CHO
























5m R = Cl
5n R = H
5o R = Br
5p R = CH3











Scheme 1 Synthesis of compounds 4a–z and 5a–s
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dimedone derivatives as zwitter ion adduct compounds 4i 
(IC50 = 17.6 ± 0.23 µM) and 5 l (IC50 = 17.2 ± 0.44 µM) 
found to be the most active compounds and showed 
more urease inhibiton poetntial than the standard com-
pound thiourea.
Molecular modeling and docking studies
In order to obtain deep insight into the binding mecha-
nism of barbituric acid derivatives within the active site of 
urease enzyme and to obtain further validations of experi-
mental results, MD simulation studies were performed.
Forty-four barbituric acid derivatives (1–44) were 
docked into the binding pocket of urease. All the com-
pounds were observed to accept analogous conforma-
tions with similar binding mode around the binding site 
of urease and these compounds were found to interact 
with nickel metal ions and the hotspot binding pocket 
residues (His137, His138, Ala169, KCX219, Asp362, 
Ala366 etc.) Visual inspection for predicted bind-
ing conformations of most potent compounds 5l and 
4i (IC50 =  17.2 ±  0.44  M and IC50 =  17.6 ±  0.23  M) 
revealed that both compounds can adopt conforma-
tion for a better fit into the binding groove of urease. 
Further analysis of the top ranked poses of these com-
pounds revealed that these compounds involved in 
multiple hydrogen bonding interactions with His138, 
Ala169, KCX219, Gly279, Asp362 and Arg338 residues. 
Compound 5i was found to be the least potent among 
the active ligands with IC50value of 210.1 ±  0.29  μM. 
Additionally; compounds 4a–4h, 4j–4r, and 4v–5e, 
5m–5q, 5h and 5k showed a good urease inhibitory 
activity. In case of most active compound 5l the amine 
moiety adjacent to the carbonyl group formed hydro-
gen bond with the side chain oxygen of modified lysine 
KCX 219 at a distance of 2.61  Å. Another hydrophil-
lic interaction found between carbonyl moiety of alde-
hyde group at para position of benzene ring and NH of 
His323 at a distance of 2.82  Å. The compound is fur-
ther stabilized by the numerous hydrophilic interac-
tions provided by catalytic residues Ala169 (2.75  Å), 
Gly279 (1.97 Å) and Asp362 (3.14 Å) NH moiety with 
carbonyl oxygen of compound 5l. Another important 
residue Arg338 formed two hydrogen bonds with car-
bonyl oxygen of pyrimidine ring at a distance of 2.32 
and 3.03 Å, respectively. The best docked conformation 
of compound 5l predicted by MOE showed that the 
compound is deeply inserted within the urease binding 
site which is further stabilize by multiple hydrophilic 
and hydrophobic interactions, contributing to the 
higher activity of this compound. The binding mode of 
5l is represented in Fig. 1a.
The binding mechanism of compound 4i reveals that 
multiple hydrogen bonding interactions found between 
ligand and hotspot residues. The carbonyl of pyrimidine 
moiety engaged in hydrogen bonding interaction with 
the NH of KCX219 and Arg338 at a distance of 2.71 and 
2.35  Å, respectively. The NH of pyrimidine ring form 
hydrogen bond with the oxygen of Ala169, Gly279 and 
Asp362 at a distance of 2.88, 1.91 and 3.38  Å, respec-
tively. Moreover these interactions are further stabilized 
by polar interactions with the His138. Due to the absence 
of aldehyde group at meta position of compound 4i, it is 
unable to make hydrophillic interaction with His323. The 
binding pattern of 4i in the ligand binding site of urease 
is shown in Fig. 1b.
Compounds 4j and 5n adopted a similar binding mech-
anism to 5l with some minor changes. The carbonyl oxy-
gen of these compounds are hydrogen bonded to NH of 
Arg338 (2.19 and 2.13 Å) and KCX219 (2.7 and 2.91 Å), 
while NH of pyrimidine moiety of these compounds are 
engaged in hydrogen bond interactions with Ala169 (2.86 
and 2.88 Å), Gly279 (1.87 and 1.96 Å) and Asp 362 (3.01 
and 3.33 Å) as observed in 5l (Fig. 1). The non substituted 
benzene ring of the molecule is exposed to the surface 
and not found to be involved in such interactions. The 
docked orientation of 4j and 5n is shown in Fig. 1c, d.
Table 1 In vitro urease inhibiton activity of  compounds 
4a–z and 5a–s
Compound Urease inhibition 
IC50 ± SEM [µM]
Compound Urease inhibition 
IC50 ± SEM [µM]
4a 39.3 ± 0.36 4x 38.5 ± 0.28
4b 34.4 ± 1.57 4y 83.4 ± 1.00
4c 54.2 ± 0.47 4z 39.8 ± 1.38
4d 31.6 ± 0.79 5a 74.5 ± 0.88
4e 27.5 ± 0.12 5b 29.7 ± 0.67
4f 54.2 ± 0.83 5c 61.4 ± 1.12
4g 28.5 ± 0.41 5d 51.3 ± 0.45
4h 40.3 ± 0.32 5e 39.8 ± 0.75
4i 17.6 ± 0.23 5f 106.4 ± 1.49
4j 22.3 ± 0.73 5g 170.7 ± 1.55
4k 25.8 ± 0.23 5h 49.0 ± 0.55
4l 22.7 ± 0.20 5i 210.1 ± 0.29
4m 39.3 ± 0.79 5j 72.6 ± 0.59
4n 41.2 ± 0.58 5k 43.8 ± 0.33
4o 83.0 ± 0.66 5l 17.2 ± 0.44
4p 39.7 ± 0.70 5m 65.9 ± 0.61
4q 24.6 ± 0.42 5n 23.7 ± 0.57
4r 27.5 ± 0.19 5o 34.6 ± 0.79
4s 109.7 ± 1.10 5p 27.4 ± 0.54
4t 142.1 ± 0.64 5q 41.6 ± 0.41
4v 52.2 ± 1.26 5r 82.8 ± 0.72
4w 59.4 ± 0.98 5s 123.2 ± 0.37
STD. Thiourea 21.2 ± 1.3
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To explain the inactivity of compounds 4s–4t, 5f–5g, 
5i and 5s all the inactive compounds were also docked in 
the urease binding cavity by using MOE. By docking pose 
analysis, it is evident that all the inactive compounds 
were poorly occupied in the binding site. The carbonyl 
oxygen of 4t, 5g and 5i is replaced by an alkyl group as a 
result, hydrogen bonding interactions with catalytic resi-
dues are lost. The docked poses are shown in Fig.  1e, f. 
Similarly, the compounds 4s, 5i containing nitro group 
at R1 position instead of electron donating group may 
Fig. 1 The docked poses of urease inhibitors: most active 5l (a), 4i (b), active 5n (c), 4j (d) and least active 4t (e), 5g (f). The interacting residues are 
presented in yellow stick while the ligands are shown in purple sticks
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be one of the reasons for the inactivity of these com-
pounds. These compounds interact with nickel ions but 
interactions with the catalytic residues are not as effec-
tive as observed in case of active compounds and shown 
in Fig.  1e, f ). Consequently, absence of hydrogen bond 
interactions of these inactive compounds with crucial 
residues Ala169, Arg338 and Asp362 might be the reason 
for the inactivity of these compounds in the in vitro assay.
Molecular dynamic simulations
In order to understand the binding mechanism of barbitu-
ric acid derivatives molecular dynamic (MD) simulation 
was performed. The enol form of barbituric acid derivatives 
is found to be more stable during MD simulation as com-
pared to its keto form. The keto form established only a 
weak interaction with nickel as compared to the enol. Inter-
action with nickel ion is crucial for inhibitory mechanism of 
urease inhibitors. The two forms disagree after 500 ps simu-
lation as the distance between Ni and keto form increases 
gradually. To obtain further interaction pattern for two dif-
ferent form of barbituric acid derivatives, docking was also 
performed with both the possible forms. In the docking 
experiment, similar interactions with catalytic residues were 
observed except interaction with nickel metal. The obtained 
conformation explained the three dimensional structure of 
protein, which can be changed without fluctuating covalent 
bonds. The RMSD plot of protein conformation verses time 
for both the complexes is given in Fig. 2, which support the 
stability of enol form as nickel complex.
Conclusion
This study conclude that a simple one step chemis-
try can generate extra-ordinary array bioactive com-
pounds. During this study, we synthesized barbituric 
acid derivatives by simple filtration and evaluated for 
their urease inhibitory activity. Compounds (4a–4z 
Fig. 2 The RMSD plot of barbituric acid derivatives enol and keto 
complexes. Red color represents the enol form and black color repre‑
sents the keto form RMSD
and 5a–s) were evaluated for their urease inhibi-
tion potential in  vitro against the standard compound 
thiourea (IC50  =  128.8  ±  2.1  µM). Compounds 4i 
(IC50 = 17.6 ± 0.23 µM) and 5l (IC50 = 17.2 ± 0.44 µM) 
were found to be the most active members of the series 
with several fold more urease inhibition activity than the 
standard compound thiourea. The promising result of the 
current study indicates that barbituric acid derivatives 
can be investigated for the treatment of urease associated 
complications, such as peptic ulcer.
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